|1.||Kagiya, Tsutomu V: 5 articles (01/2011 - 12/2003)|
|2.||Yamazaki, Hideya: 4 articles (04/2013 - 01/2011)|
|3.||Kagiya, Tsutomu: 3 articles (04/2013 - 02/2013)|
|4.||Nakamura, Satoaki: 3 articles (04/2013 - 02/2013)|
|5.||Aibe, Norihiro: 3 articles (04/2013 - 02/2013)|
|6.||Yoshida, Ken: 3 articles (04/2013 - 02/2013)|
|7.||Tatsuzaki, Hideo: 3 articles (01/2007 - 06/2002)|
|8.||Dobrowsky, Werner: 3 articles (01/2007 - 06/2002)|
|9.||Xiao, Yu-Ping: 2 articles (01/2015 - 07/2013)|
|10.||Zeng, Yue-Can: 2 articles (01/2015 - 07/2013)|
01/01/2007 - "AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: results of an IAEA multicentre randomised trial."
12/01/2004 - "Addition of sanazole to hypoxic tumor cell suspension resulted in the increase of nitrite content in tissue culture medium. "
12/01/2003 - "The radiation sensitization property of sanazole was discernible by comparing the relative tumor diameter following irradiation after i.p. "
12/01/2003 - "The administration of sanazole to tumor-bearing animals enhanced the radiation-induced internucleosomal fragmentation in the nuclear genome of tumor cells. "
12/01/2001 - "AK-2123 has no own antitumor effect on investigated tumors and cannot modify the sensitivity of the parent tumor P388 to MMC."
|2.||Uterine Cervical Neoplasms (Cancer of the Cervix)
04/01/2005 - "AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cancer cervix: initial results of an IAEA multicentre randomized trial."
06/01/2002 - "Sanazole as a sensitizer of hypoxic cells with radical radiation in the treatment of advanced cancer of cervix an Indian experience."
01/01/1992 - "Based on a clinical differential effect of the action of a new hypoxic cell radiosensitizer, AK-2123 (a 3-nitro-1,2,4-triazole), on locally advanced cervix cancer (Stage II-B and III-B), a Phase I/II clinical trial has been carried out on 80 consecutive patients. "
01/01/2007 - "A prospectively randomised trial was initiated by the International Atomic Energy Agency (IAEA) evaluating AK-2123 and radiotherapy in treatment of uterine cervical cancer stage III and IV. A total of 462 patients were randomised from 8 centres. "
04/01/2005 - "A prospectively randomised trial was initiated by the International Atomic Energy Agency (IAEA) evaluating AK-2123 and radiotherapy in treatment of uterine cervical cancer stage IIIA and IIIB. "
|4.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
03/01/2013 - "Preparation and evaluation of a ⁹⁹mTcN-PNP complex of sanazole analogue for detecting tumor hypoxia."
12/01/2004 - "Preparation and preliminary biological evaluation of a 177Lu labeled sanazole derivative for possible use in targeting tumor hypoxia."
01/01/2001 - "Technetium-99m-cyclam AK 2123: a novel marker for tumor hypoxia."
11/01/1996 - "It is concluded that hydralazine plus heat virtually eliminated a hypoxia-related radioresistance in tumours, thus removing the requirement for AK-2123 administration."
03/01/2013 - "A sanazole derivative, having a favorable single electron reduction potential (SERP) value compared to that of misonidazole, was synthesized and radiolabeled with [(99m)TcN(PNP)] precursor to evaluate its potential as a hypoxia imaging agent. "
|10.||Nitric Oxide (Nitrogen Monoxide)
|2.||Induced Hyperthermia (Thermotherapy)
|3.||Drug Therapy (Chemotherapy)